Inozyme Pharma (NASDAQ:INZY) Releases Quarterly Earnings Results

Inozyme Pharma (NASDAQ:INZY) released its quarterly earnings results on Tuesday. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.05, Zacks reports.

Inozyme Pharma Stock Performance

INZY stock traded down $0.13 during trading on Thursday, hitting $4.10. 517,110 shares of the company’s stock traded hands, compared to its average volume of 418,650. The stock has a fifty day moving average price of $5.13 and a two-hundred day moving average price of $4.92. The stock has a market capitalization of $257.19 million, a price-to-earnings ratio of -2.81 and a beta of 1.54. The company has a quick ratio of 9.84, a current ratio of 9.84 and a debt-to-equity ratio of 0.48. Inozyme Pharma has a 52 week low of $2.71 and a 52 week high of $7.80.

Analysts Set New Price Targets

Several research firms recently issued reports on INZY. Stifel Nicolaus began coverage on shares of Inozyme Pharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $16.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Inozyme Pharma in a report on Wednesday. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Inozyme Pharma in a report on Wednesday. Wedbush restated an “outperform” rating and issued a $12.00 price target (down previously from $15.00) on shares of Inozyme Pharma in a report on Tuesday. Finally, Jefferies Financial Group restated a “buy” rating and issued a $17.00 price target (up previously from $16.00) on shares of Inozyme Pharma in a report on Tuesday, August 13th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $15.71.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.